comparemela.com

Latest Breaking News On - Iapocec charles wykoff - Page 1 : comparemela.com

Keeping A Watchful Eye: Safety Reports in Geographic Atrophy Landscape

A headline year for retina disease drug development concurrently brought about research and discussion into the safety outcomes of these new agents.

United statesSan franciscoIapocec apellisDavid lallyKunzmannk apellisDilsher dhootVeeral shethIapocec charles wykoffCharles wykoffNathan steinleAvacincaptad pegolIapocec pegcetacoplanIapocec nathan steinleUniversity retinaApellis pharmaceuticalsMacula associates

Geographic Atrophy Treatment Breakthrough, Strengthened Doses Headline Historic 2023 for Ophthalmology

Chief among a flurry of clinical advances in retina disease this year were the FDA approvals of complement inhibitors for GA and a higher-dose aflibercept for diabetic retinopathy. What comes next?

United statesStanford universityCleveland clinicChristinen kayIapocec hani salehi hadIapocec apellisIapocec aleksandra rachitskayaIapocec jean francois korobelnikW lloyd clarkMarcoa zarbinIapocec charles wykoffIapocec dianaArshad khananiAleksandra rachitskayaIapocec arshad khananiCampbellp aflibercept

Pegcetacoplan for Geographic Atrophy Shows Increasing Effect at 24 Months

24-month results from OAKS and DERBY show that pegcetacoplan significantly reduced GA lesion growth with both monthly and every-other-month dosing.

United statesAvacincaptad pegolIveric bioIapocec charles wykoffCharles wykoffDrug administrationApellis pharmaceuticals incRetina consultantsApellis pharmaceuticalsPegcetacoplan injection

vimarsana © 2020. All Rights Reserved.